In conclusion, this study suggested that blocking PlGF/VEGFR-1 signaling with D16F7 mAb represents a promising strategy to counteract the metastatic potential of melanoma by inhibiting tumor-associated angiogenesis and invasion [35]. This evidence concerns the gene FLT1 and melanoma.